Ascitic fluid

PreclinicalSmall molecule

IInstitute of Liver and Biliary Sciences, India

Ascitic fluid is one of 21 small molecule programs targeting Acute-on-Chronic Liver Failure. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute-on-Chronic Liver FailureActive, not recruiting

InfusionCompleted

Acute-on-Chronic Liver FailurePreclinical

Active, not recruiting

InfusionPreclinical

Completed

Competition

Competitive Landscape

12 competitors in Acute-on-Chronic Liver Failure

#DrugCompanyPhaseTrials

Glypressin

MMallinckrodt

Approved

1 2

Vemlidy

Gilead

Preclinical

2 3

Proamatine

Takeda

Preclinical

1 4

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 5

Coreg

Akero Therapeutics

Preclinical

1 6

Tenofovir (TFV) IVR

Gilead

Preclinical

1 7

Plasma Exchange

Sanofi

Preclinical

1 8

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Preclinical

2 9

G-CSF

AArog Pharmaceuticals, Inc.

Preclinical

2 10

Prothrombin Complex Concentrate

CSL Behring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Infusion1 trial

To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02467322·80 enrolled

Acute-on-Chronic Liver Failure1 trial

Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure.

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02467348·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ascitic fluid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ascitic fluid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ascitic fluid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInstitute of Liver and Biliary Sciences, India

Ascitic fluid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Infusion1 trial

Acute-on-Chronic Liver Failure1 trial

References

Drug Info

Quick Facts

Related News